Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 2
1995 1
2003 1
2012 1
2015 1
2017 1
2018 2
2019 3
2021 1
2022 2
Text availability
Article attribute
Article type
Publication date

Search Results

15 results
Results by year
Filters applied: . Clear all
Page 1
Serum soluble CD26/DPP4 titer variation is a potential prognostic biomarker in cancer therapy with a humanized anti-CD26 antibody.
Kaneko Y, Hatano R, Hirota N, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Valleix F, Podoll T, Umezawa Y, Takao S, Iwata S, Hosono O, Taguchi T, Yamada T, Dang NH, Ohnuma K, Angevin E, Morimoto C. Kaneko Y, et al. Among authors: podoll t. Biomark Res. 2021 Mar 23;9(1):21. doi: 10.1186/s40364-021-00273-0. Biomark Res. 2021. PMID: 33757558 Free PMC article.
Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects.
Wong S, Krejsa C, Lee D, Harris A, Simard E, Wang X, Allard M, Podoll T, O'Reilly T, Slatter JG. Wong S, et al. Among authors: podoll t. Clin Pharmacol Drug Dev. 2022 May;11(5):640-653. doi: 10.1002/cpdd.1070. Epub 2022 Feb 16. Clin Pharmacol Drug Dev. 2022. PMID: 35172043 Clinical Trial.
Evaluation of the Drug-Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP-5862, Using a Physiologically-Based Pharmacokinetic Modeling Approach.
Zhou D, Podoll T, Xu Y, Moorthy G, Vishwanathan K, Ware J, Slatter JG, Al-Huniti N. Zhou D, et al. Among authors: podoll t. CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):489-499. doi: 10.1002/psp4.12408. Epub 2019 May 12. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31044521 Free PMC article.
First-in-human phase 1 of YS110, a monoclonal antibody directed against CD26 in advanced CD26-expressing cancers.
Angevin E, Isambert N, Trillet-Lenoir V, You B, Alexandre J, Zalcman G, Vielh P, Farace F, Valleix F, Podoll T, Kuramochi Y, Miyashita I, Hosono O, Dang NH, Ohnuma K, Yamada T, Kaneko Y, Morimoto C. Angevin E, et al. Among authors: podoll t. Br J Cancer. 2017 Apr 25;116(9):1126-1134. doi: 10.1038/bjc.2017.62. Epub 2017 Mar 14. Br J Cancer. 2017. PMID: 28291776 Free PMC article. Clinical Trial.
Structure based design of an in vivo active hydroxamic acid inhibitor of P. aeruginosa LpxC.
Warmus JS, Quinn CL, Taylor C, Murphy ST, Johnson TA, Limberakis C, Ortwine D, Bronstein J, Pagano P, Knafels JD, Lightle S, Mochalkin I, Brideau R, Podoll T. Warmus JS, et al. Among authors: podoll t. Bioorg Med Chem Lett. 2012 Apr 1;22(7):2536-43. doi: 10.1016/j.bmcl.2012.01.140. Epub 2012 Feb 16. Bioorg Med Chem Lett. 2012. PMID: 22401863
15 results